BioSpace News Archive

Heidelberg Pharma AG (FSE: WL6) today announced that the partner University of Texas, MD Anderson Cancer Center, Houston, TX, USA, (MD Anderson), was granted patent rights related to the diagnosis and treatment of patients with RNA polymerase II deletion

Harrington Discovery Institute at University Hospitals and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2020 ADDF-Harrington Scholar Award.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of Steven Gannon to its Board of Directors.

EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and Immunology (CVI)).

City of Hope scientists have developed and tested the first chimeric antigen receptor (CAR) T cell therapy using chlorotoxin (CLTX), a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published today in Science Translational Medicine

Physicians’ Education Resource® (PER®), a leading resource for continuing medical education, will conduct a satellite symposium titled “Severe Asthma Through the Ages: Personalized Management for Difficult-to-Treat Children, Adolescents, and Adults” adjunct to the 2020 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its AgilonTM moldable bone grafting product.